更新于：2024-12-26
Aceclofenac
醋氯芬酸
更新于：2024-12-26
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H13Cl2NO4 |
InChIKeyMNIPYSSQXLZQLJ-UHFFFAOYSA-N |
CAS号89796-99-6 |
关联
41
项与 醋氯芬酸 相关的临床试验A post approval observational study to assess the impaCt Of fixed dose coMbination of Trypsin: Chymotrypsin+ Aceclofenac + Paracetamol In Outpatient SEttings of India (COMPOSE I) - Compose I
A Comparative Evaluation of The Effect of Low-Level LASER Therapy, LASER-Activated Irrigation and Preoperative Aceclofenac on Post Endodontic Pain After Single Visit Root Canal Treatment - A Randomized Controlled Trial. - NIL
醋氯芬酸片（100mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 醋氯芬酸 相关的临床结果
登录后查看更多信息
100 项与 醋氯芬酸 相关的转化医学
登录后查看更多信息
100 项与 醋氯芬酸 相关的专利（医药）
登录后查看更多信息
536
项与 醋氯芬酸 相关的文献（医药）2024-12-16Journal of biomolecular structure & dynamics
Water dynamics on the structural properties of some NSAID’s with leucine in the picosecond region using time domain spectroscopy
Article
作者: Alwaleedy, Suad ; Karale, Ravikant R. ; Kumbharkhane, Ashok C. ; Kabara, Komal B. ; Sarode, Arvind V. ; Kamble, Savita ; Al-Hamdani, Saeed
Concentration-dependent dielectric response for non-steroidal anti-inflammatory drugs (NSAIDs): Aceclofenac (ACF) and Diclofenac (DCF) in the aqueous leucine solution have been reported at different concentrations and temperatures (298.15 K to 283.15 K). The time domain reflectometry technique in the frequency region of 1 GHz to 30 GHz was used for the present study. Complex permittivity (ε*), static dielectric constant (ε), dielectric relaxation time (τ), dipole moment (μ) and Kirkwood correlation factor (g) have been calculated and discussed in terms of the molecular interaction of water and the used drugs. To give more insights into the structural dynamics of drug-induced amino acids, the study includes molar enthalpy of activation (ΔH), entropy of activation (ΔS), and free energy of activation (ΔF). The overall study concludes that the drug (DCF) having a potent inhibitor of cyclooxygenase found a higher static dielectric constant (ε0) than that of the drug (ACF) having more carbon (C), hydrogen (H), and oxygen (O) in the chain, which is more efficient in controlling pain.Communicated by Ramaswamy H. Sarma.
2024-12-01Heliyon
Synthesis and pharmacological evaluation of heteroarylamide derivatives as potential analgesic, anti-inflammatory, antidiarrheal and cytotoxic agents
Article
作者: Rahman, S M Abdur ; Saha, Poushali ; Hossain, A S M Monjur Al ; Rahman, Fahad Imtiaz ; Spriha, Sabiha Enam ; Tabassum, Nazifa ; Al Hossain, ASM Monjur
Six heteroarylamide derivatives were synthesized in good yields and screened for several biological activities. Compounds 1-5 demonstrated analgesic activity with percentage inhibition of writhing between 77.10 and 95.79 %, comparable to that of the standard aceclofenac having 91.12 % writhing inhibition. Evaluation of anti-inflammatory activity unveiled that compound 4 exhibited 36.9 %, 64.17 %, 82.9 % and 93.9 % inhibition of paw edema as compared to aceclofenac's inhibition of 35.5 %, 78.6 %, 79.3 % and 91.2 % at the 1st, 2nd, 3rd and 4th hours, respectively. Compounds 5 and 6 exerted considerable antidiarrheal effects with 85.00 % and 71.67 % inhibition of defecation at 25 mg/kg dose, respectively, whereas, the standard loperamide showed 85.00 % inhibition. Compounds 4-6 manifested promising activity in brine shrimp lethality bioassay as well as in trypan blue dye exclusion assay, resulting in 10-20 % cell viability on HeLa cell line and compound 5 was found to have the lowest IC50 of 281.96 μM in the MTT assay. Molecular docking analysis suggested that certain macromolecular targets such as cyclooxygenase-2, muscarinic M3 receptor and matrix metalloproteinase 9 (MMP9) might be involved for the observed activities. As predicted by in silico ADME/T analysis, the compounds also possessed good pharmacokinetic properties.
2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Strategic development of aceclofenac loaded organosomes for topical application: An explorative ex-vivo and in-vivo investigation for arthritis
Article
作者: Katare, O P ; Raza, Kaisar ; Katare, O.P. ; Thakur, Kanika ; Thakur, Anil ; Singh, Vijay ; Nirbhavane, Pradip ; Sharma, Gajanand
Present study intends to develop aceclofenac-encapsulated organosomes (OS), which consist of phospholipids coupled with a combination of organic solvents, for the management of arthritis. The formulation was characterized and tested for efficacy using formalin-induced hyperalgesia, air pouch, and CFA-induced arthritic rat models. OS system exhibited spherical dimension, nanometric size with low PDI (278.3 ± 12.21 nm; 0.145), zeta potential (-24.56 ± 7.53 mV), drug entrapment (85.62 ± 7.2 %) and vesicles count (4.2x104 mm3). The gelled OS formulation demonstrated increased drug permeability and accumulation rate (51.77 ± 7.1 % and 396.19 ± 59.21 µg/cm2) compared to the MKT product (102.93 ± 13.78 µg/cm2 and 16.14 ± 4.3 %). Dermatokinetic assessments exhibited significantly higher drug levels in dermal layers compared to MKT product (p < 0.001), and CLSM studies further supported the OS system's deeper penetration. The results of arthritic index significantly better (9 times) in the OS-treated group than the MKT product. OS system treatment significantly reduced biochemicals and cytokines levels, such as CRP, ESR, TLC, lymphocytes, TNF-α, IL-6, and IL-1β to levels of the control group (p < 0.001). Pseudoplastic behaviour of the developed product was indicated by the rheological results, and it also demonstrated biocompatibility through skin compliance studies. Based on the current findings, it appears that OS may be a better choice for managing arthritis and related inflammations.
100 项与 醋氯芬酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 平滑肌瘤 | 欧盟 | 2018-08-27 | |
| 平滑肌瘤 | 冰岛 | 2018-08-27 | |
| 平滑肌瘤 | 列支敦士登 | 2018-08-27 | |
| 平滑肌瘤 | 挪威 | 2018-08-27 | |
| 风湿性疾病 | 西班牙 | - | 1993-05-19 |
| 强直性脊柱炎 | - | - | 1992-01-01 |
| 骨关节炎 | - | - | 1992-01-01 |
| 类风湿关节炎 | - | - | 1992-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 120 | Aceclofenac 100 mg twice a day | 積窪繭憲鑰鹽繭構遞鑰(壓鑰遞觸選選獵觸廠壓) = Adverse events of therapy were mild and not require discontinuation of therapy 壓繭衊蓋簾壓願鹽淵衊 (齋齋製齋鬱範製憲鑰廠 ) | 积极 | 2020-08-20 | ||
N/A | - | NSAIDs | 窪積蓋醖鑰餘憲獵齋艱(觸襯鹹鹽窪選膚獵鹽獵) = 願網淵鹽鏇鹽蓋廠網襯 鹹襯憲壓鹹鏇糧築膚鑰 (積衊襯簾憲膚窪顧願鹽, 1.7 ~ 3.1) | - | 2015-06-10 | ||
临床4期 | 143 | 遞鏇鬱壓簾製醖製窪艱(繭鹹憲壓遞憲製顧糧鏇) = 鑰餘觸齋鹽築範鑰鹹蓋 構齋齋觸壓膚獵鑰襯廠 (夢廠壓夢願艱餘構夢鹽, 簾遞餘願憲網艱淵製夢 ~ 淵製齋艱鬱窪醖構壓憲) 更多 | - | 2013-06-24 | |||
N/A | 200 | 廠壓構蓋鹽簾積襯蓋積(鑰窪蓋襯築鑰糧鬱鏇積) = Adverse effects were noted in 3% of Aceclofenac treated OA patients and in 12% subjects treated with Diclofenac 憲鬱選網積鏇簾願蓋鑰 (壓積淵觸鑰構製遞膚糧 ) | - | 2012-06-06 | |||
N/A | - | 簾衊繭衊顧範遞願構糧(顧窪鑰鏇鹽廠襯餘觸襯) = 構築鹹構膚願鹽鹽憲淵 遞餘廠衊蓋淵鑰蓋窪遞 (廠積蓋襯窪鬱壓範觸遞 ) 更多 | 积极 | 2002-06-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用